Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Viavi Solutions Inc. Common Stock (VIAV) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Viavi Solutions Inc. Common StockTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Viavi Solutions Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Viavi Solutions Inc. Common Stock trades at $37.68 (market cap $10.15B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Viavi Solutions Inc. Common Stock is far larger — about 5.6× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Viavi Solutions Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Viavi Solutions Inc. Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

VIAVVIR
Market Cap
$10.15B$1.80B
Volume
4,601,2221,782,836
Sector
TechnologyHealth
52-Week High
$55.33$11.78
52-Week Low
$13.01$5.12
Typical Hold Time
6 Days0 Days
Enterprise Value
$10.20B$1.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Viavi Solutions Inc. Common Stock

VIAVI Solutions (VIAV) trades at $41.28, down 1.13% on the day, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong revenue growth with fiscal 2026 revenue reaching $1.52B (up 40% YoY) and has beaten earnings estimates for three consecutive quarters. Recent developments include a U.S. Army contract for defense testing and expanded partnerships in network validation, positioning VIAV for growth in AI data center and defense markets.

While analyst consensus remains strongly bullish with a $60.25 price target (78.95% buy ratings), investors face risks from negative net income margins (-2%) and elevated valuation metrics (P/S 6.24, EV/EBITDA 60.68). The stock's outlook depends on continued execution in high-growth segments and margin improvement to justify current valuations amid competitive pressures.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VIAV

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Viavi Solutions Inc. Common Stock

Viavi Solutions provides network testing, monitoring, and optical technologies. Its products help communications providers, equipment makers, and enterprises build and maintain networks.

Read more on VIAV →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →